FAP and neoplasm: Furthermore, a DC vaccine that encodes an A20-specific short hairpin RNA (shRNA) to enhance DC function, targets FAP and the tumor antigen tyrosinase-related protein 2 (TRP-2), has demonstrated its ability to enhance tumor infiltration of CD8+ T cells and to induce robust FAP- and TRP-2-specific T-cell responses in a B16 melanoma model [230].